期刊文献+

EphA2、CD34、D2-40在卵巢上皮性肿瘤中的表达及其与临床病理的关系 被引量:3

The expressions of EphA2,CD34 and D2-40 in ovarian epithelial neoplasms and their relationships with clinicopathology
下载PDF
导出
摘要 目的检测EphA2、CD34、D2-40在卵巢上皮性肿瘤中的表达,探讨其与临床病理因素的关系。方法采用免疫组化方法检测10例正常卵巢上皮、48例良性卵巢上皮性肿瘤、47例交界性卵巢上皮性肿瘤以及205例恶性卵巢上皮性肿瘤组织中EphA2、CD34及D2-40的表达,并计数微血管密度(MVD)及微淋巴管密度(LMVD)。结果 (1)正常卵巢组织中EphA2、CD34-MVD、D2-40-LMVD的表达较卵巢上皮性肿瘤组织显著降低,差异有统计学意义(χ2=14.662 4,P=0.002)。(2)恶性卵巢上皮性卵巢肿瘤组织中EphA2的表达、CD34-MVD、D2-40-LMVD与肿瘤的临床分期、分化程度、有无淋巴结转移有关,差异有统计学意义(P<0.05),但与患者年龄无关(P>0.05)。(3)恶性卵巢上皮性肿瘤组织中EphA2不同表达程度组间CD34-MVD、D2-40-LMVD差异有统计学意义(F=4.33,P=0.005 5;F=7.91,P=0.000 1)。EphA2的表达与CD34-MVD、D2-40-LMVD呈正相关(r=0.220 4,P=0.001 5;r=0.297 8,P=0.000 0)。且在恶性卵巢上皮性肿瘤组织中CD34-MVD与D2-40-LMVD呈正相关(r=0.534 0,P=0.000)。结论 EphA2的过表达一方面可以促进肿瘤细胞的增殖能力,另一方面可以促进肿瘤组织中新血管及新淋巴管的产生,新生的血管及淋巴管在肿瘤细胞的侵袭及转移过程中起着相辅相成的作用。 Objective To examine the expressions of EphA2,CD34 and D2 40 in ovarian epithelial neoplasms, and investigate their relationships with clinicalpathologh. Methods SP immunohistochemical staining was used to examine the expressions of E phA2, CD34 and D2 40 in 10 normal ovarian specimens, 48 benigh ovarian specimens, 47 boundary ovarian specimens and 205 malig- nant ovarian specimens. Results (1) The expressions of EphA2,CD34 and D2-40 in normal ovarian tissues were higher than in o- varian epithelial neoplasms(P(0.01). (2) The expressions of CD34 MVD,D2-40 LMVD in the maglignant ovarian epithelial neo plasms were positively related to clinical stage, differential and lymph node metastasis (P〈0.05). But no statistioally difference was found between them with the patientslage(P〉0. 05). (3)A statistically differenee of MVD and LMVD were found between the different grade expressions of EphA2 in malignant Ovarian(P〈0. 01). And the expressions of EphA2 were positively correlated with CD34 MVD and D2 40-LMVD(P〈0.01). The expressions of CD34 MVD and D2-40 LMVD were positively correlated with each other in malignant neoplasms(P〈0.01). Conclusion EphA2 over-expression on the one hand could promote the proliferation of tumor cells.
出处 《重庆医学》 CAS CSCD 北大核心 2011年第11期1055-1057,1060,F0003,共5页 Chongqing medicine
关键词 卵巢肿瘤 病理学 临床 EPHA2 CD34 D2-40 ovarian neoplasms pathology, clinical EphA2 CD34 D2-40
  • 相关文献

参考文献5

二级参考文献55

  • 1牛彦锋,卢晓明,王国斌,杨鹏.大肠癌中缺氧诱导因子-1α与环氧合酶-2相关性的研究[J].腹部外科,2004,17(4):244-246. 被引量:4
  • 2关菊莲.动静脉留置针腹壁穿刺给药法在卵巢癌化疗中的应用[J].临床误诊误治,2004,17(12):843-844. 被引量:1
  • 3王春澄.髂内动脉插管灌注抗癌药物治疗晚期卵巢癌[J].社区医学杂志,2005,3(4):78-79. 被引量:1
  • 4[1]Brantley-Sieders DM,Fang WB,Hicks DJ,et al.Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression[J].FASEB J,2005,19(13):1884-1886.
  • 5[2]Thaker PH,Deavers M,Celestino J,et al.EphA2 expression is associated with aggressive features in ovarian carcinoma[J].Clin Cancer Res.2004,10 (15):5145-5150.
  • 6[3]Lin YG,Han LY,Kamat AA,et al.EphA2 overexpression is associated with angiogenesis in ovarian cancer[J].Cancer.2007,109 (2):332-340.
  • 7[4]Herath NI,Spanevello MD,Sahesan S,et al.Over-expression of Eph and ephrin genes in advanced ovarian cancer:,ephrin gene expression correlates with shortened survival[J].BMC Cancer.2006,6:144.
  • 8[5]Makarla PB,Saboorian MH,Ashfaq R,et al.Promoter hypermethylation profile of ovarian epithelial neoplasms[J].Clin Cancer Res.2005,11(15):5365-5369.
  • 9[6]Faleiro-Rodrigues C,Macedo-Pinfo I,Pereira D,et al.Association of E-cadherin and beta-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas.Hum Pathol.2004,35(6):663-669.
  • 10[7]Saito T,Masuda N,Miyazaki T,et al.Expression of EphA2 and Ecadherin in colorectal cancer:correlation with cance rmetastasis[J].Oncol Rep,2004,11(3):605-611.

共引文献15

同被引文献46

  • 1QIAN Ya-yun,LIU Yan-qing Institute of Traditional Chinese Medicine & Western Medicine,Yangzhou University,Yangzhou 225009,China.Inhibition of Celastrus orbiculatus Extracts on VEGF Expression in Hepatoma Cells of Mice[J].Chinese Herbal Medicines,2010,2(1):72-76. 被引量:11
  • 2周明芳,冯正直,程天民.慢性应激抑郁复合皮肤创伤对大鼠行为及体重的影响[J].创伤外科杂志,2007,9(2):154-156. 被引量:4
  • 3Hirm H, Maru Y, Hawara K,et al. A novel putative tyrosine kinase receptor encoded by the eph gene[ J]. Science,1987,238 (4834):1717-1720.
  • 4Tandon M, Vemula SV, Mittal SK. Emerging strategies for EphA2 receptor targeting for cancer therapeutics[ J ]. Expert Opin Ther Targets,2011 , 15 ( 1 ) :31-51.
  • 5Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signaling and beyond [ J ]. Nat Rev Cancer, 2010,10 ( 3 ) : 165- 180.
  • 6Mosch B, Reissenweber B, Neuber C, et al. Eph receptors and ephrin ligands: Important players in angiogenesis and tumor an- g'ioenesis[ J]. J Oncol,2010,2010 : 135285.
  • 7Singla N, Erdjument-Bromage H, Himanen JP, et al. A semi- synthetic Eph receptor tyrosine kinase provides insight into lig- and-induced kinase activation [ J ]. Chem Biol, 2011,18 ( 3 ) : 361-371.
  • 8Lindberg RA, Hunter T. cDNA cloning and characterization of Eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases [ J]. Mol Cell Biol, 1990,10 (12) :6316-6324.
  • 9Shahzad MM, Lu C, Lee JW, et al. Dual targeting of EphA2 andFAK in ovarian carcinoma[ J]. Cancer Biol Ther,2009,8 ( 11 ) : 1027-1034.
  • 10Thaker PH, Deavers M, Celestino J, et al. EphA2 expression is associated with aggressive features in ovarian carcinoma[ J]. Clin Cancer Ras ,2004,10 ( 15 ) :5145-5150.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部